Metis TechBio Co., Ltd. (SEHK: 7666)
Health Care · Biotechnology · CN
HK$12.11
+0.92% today · -49.1% 1Y
Metis TechBio Co., Ltd. (SEHK: 7666) operates in the Biotechnology industry within the Health Care sector. The company is valued at $1.83B and employs 5 people.
Over the last twelve months the share price has lost 49.1%, trading between 9.46 and 29.98.
7666 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $1.83B
- Revenue (TTM)
- $15.01M
- P/E
- —
- EPS
- -4.66
- Dividend yield
- —
- Beta (5Y)
- —
- 52-week high
- HK$29.98
- 52-week low
- HK$9.46
- Avg volume (3M)
- —
- Shares outstanding
- 1.18B
- Employees
- 5
- Next earnings
- —
About Metis TechBio Co., Ltd.
Metis TechBio Co., Ltd., founded in 2020 and headquartered in Beijing, China, (previously Hangzhou Jitai Pharmaceutical Technology Co., Ltd.) specializes in the advanced research and development of AI-powered nanomaterials. The company's core mission is to facilitate the delivery and application of active agents within carbon-based life forms, operating in both the Chinese Mainland and the United States. Central to its offerings is NanoForge, a comprehensive suite of interconnected technologies that includes a novel lipid library, foundational artificial intelligence models, METiSAIAgent, cutting-edge quantum chemistry and molecular dynamics simulations, and AI-driven screening platforms. Furthermore, Metis TechBio has developed specialized platforms like AiTEM, AiLNP, and AiRNA. These tools are crucial for simulating, predicting, and interpreting interactions at the nanoscale, thereby enabling the precise design, optimization, and validation of sophisticated nanomaterials and their associated payloads. The company provides its services through a three-tiered system: a foundational dry-wet data layer supported by integrated laboratory infrastructure, a model layer featuring METiS AI foundational models, and an application layer known as METiSAgentv. Metis TechBio primarily serves a diverse clientele, including pharmaceutical companies, biotechnology firms, and medical research institutions.
- ISIN
- CNE100007LD1
- Founded
- 2020
- Listed since
- May 13, 2026
- Exchange
- The Stock Exchange of Hong Kong Ltd.
- Currency
- HKD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $265.80 | +0.00% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $444.00 | +0.40% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $148.10 | -0.45% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $551.33 | -0.27% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $832.63 | -0.11% |
| argenx SEENXTBR: ARGX | $64.17B | €903.40 | +2.75% |
| Moderna, Inc.NasdaqGS: MRNA | $63.41B | $155.51 | -2.09% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
Figures last refreshed Aug 18, 2026.